📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding MD

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	1.53M	$32.8M	0.05%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 3 quarters analysed

Q3 2025

Confident Specific

Management repeatedly emphasizes that Q3 results 'exceeded our expectations' and that they 'do not view us as being at a peak,' while also acknowledging 'significant healthcare headwinds.' The CEO provides very detailed, concrete evidence of competitive differentiation (research publications, BabySteps data, clinician numbers) rather than vague optimism.

Q4 2025

Confident Vague

Management repeatedly used words like 'strong', 'very strong', 'great', but when pressed for granular detail on drivers (e.g., variable comp, ACA impact, volume decline) they deferred to 'tough comp' or said it is 'very difficult to quantify'. Guidance is specific ($1.9B revenue, $280-300M EBITDA) but built on steady assumptions with no explicit margin expansion levers.

Q1 2026 latest

Confident Specific

Management cited specific numbers (4% pricing, $58M EBITDA) and reaffirmed $280-300M guidance, while acknowledging potential headwinds from RCM collections tail off and hospital pressures.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains intact but with tempered optimism. Strong pricing and EBITDA beat in Q1 underscore execution, but volume declines and uncertainty around tax subsidy lapse warrant caution. Management’s reaffirmation of guidance suggests confidence that positive factors outweigh near-term risks. The emphasis on quality and new leadership may strengthen long-term hospital partnerships. Key to watch: whether pricing normalizes in H2, volume trends stabilize, and payer mix holds up. The buyback signals capital allocation discipline, but M&A execution will be tested.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 3 quarters Full tone analysis in Intelligence →

📊 MIXED Pediatrix Q1 2026 adjusted EBITDA $58M; full-year outlook $280M-$300M as pricing up 4%.

Revenue & Profitability

Q1 2026 adjusted EBITDA was $58 million. Full-year 2026 adjusted EBITDA outlook is $280 million to $300 million. Pricing grew 4% year-over-year. Operating cash flow was negative $130 million in Q1 (due to incentive compensation). Net leverage stood at 1.3x, with cash of about $200 million and net debt of $385 million. DSO improved to 42.5 days, down over 5 days year-over-year.

Outlook

Management reaffirmed the full-year adjusted EBITDA range of $280M-$300M. While hospital systems broadly face headwinds from patient volume and revenue declines, Pediatrix has not yet seen signs of weakness from the tax subsidy lapse. Pricing is expected to moderate in the second half as RCM cash collection benefits lap. Contract revenue conversations are getting tougher but remain a positive contributor.

Growth Drivers

Growth is driven by same-unit pricing up 4% (from RCM cash collections, contract admin fees, favorable payer mix, and higher acuity), plus net non-same unit activity from acquisitions and organic expansion. The company sees major opportunities in teleservices and obstetrics nationwide. Recent acquisitions are performing better than initial projections.

Balance Sheet & CapEx

Not discussed in this earnings call. The company deployed $21 million in share repurchases during Q1. No explicit capital expenditure guidance was provided.

Margins

Adjusted EBITDA margin trajectory was not quantified. Practice-level salary and benefits expenses increased $9 million year-over-year (3% net salary growth). G&A rose slightly, while D&A increased modestly. Management expects adjusted EBITDA for the remaining three quarters to be fairly ratable.

Key Risks

Risks include potential headwinds from the lapse of tax subsidies for health insurance (though not yet observed), volume declines in same-unit services (NICU days down about 1%), and increasing difficulty in negotiating contract administrative fees with hospitals. Macro pressures on hospital systems could also affect Pediatrix.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-04

Adjusted EBITDA reached $76M in Q2 2026, with revenue up 4% year-over-year, driven by improved payer mix, RCM collections, and higher acuity. Full-year EBITDA guidance is reaffirmed, and share repurchases continue as the company focuses on tele-hybrid medicine and acquisition opportunities.

Q1 2026 Q1 2026 2026-05-05

Q1 delivered strong adjusted EBITDA of $58M, driven by 4% pricing growth and favorable payer mix, offsetting modest volume declines. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, with pricing expected to remain flat as RCM cash collection impact tapers.

Q4 2025 Q4 2025 2026-02-19

Q4 2025 capped a strong year with adjusted EBITDA of $66M and full-year $276M, driven by favorable payer mix, acuity, and disciplined cost control. 2026 guidance projects flat revenue at $1.9B and 5% EBITDA growth, with steady operational metrics and no M&A included.

Q3 2025 Q3 2025 2025-11-03

Adjusted EBITDA for Q3 2025 exceeded expectations at $87 million, driven by strong pricing, collections, and expense controls. Portfolio restructuring and acquisitions enhanced focus and performance, while full-year adjusted EBITDA guidance is set at $270–$290 million.

Q2 2025 Q2 2025 2025-08-05

Q2 2025 adjusted EBITDA exceeded expectations, driven by strong same-unit revenue and NICU growth, while portfolio restructuring reduced total revenue. Full-year EBITDA guidance was raised, cash flow and balance sheet remain strong, and management is confident navigating regulatory and market headwinds.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.